ABSTRACT
Introduction 326 Haemostatic changes of pregnancy 326 Hereditary thrombophilia 327 Acquired thrombophilia 327 Hemostasis and mechanism for adverse pregnancy
outcome 329 Thrombophilia and adverse pregnancy outcome 330
Antithrombotic therapy 333 Therapeutic interventions for acquired and inherited
thrombophilia 334 Screening for inherited thrombophilia in pregnancy 335 Conclusion 335 References 336
There is increasing recognition that thrombophilias may contribute to abnormal placentation and placental damage. Early in pregnancy this may manifest as miscarriage, which may be recurrent. In later pregnancy, thrombophilias have been associated with stillbirth, preeclampsia, placental abruption, and intrauterine growth restriction (IUGR). These complications are the leading causes of maternal and fetal adverse pregnancy outcome, with a significant psychosocial impact and economic burden secondary to preterm delivery. The aim of this chapter is to review the contribution of thrombophilia to adverse perinatal outcomes and address the role of potential therapeutic interventions.
